Fessenden et al. Journal for ImmunoTherapy of Cancer (2018) 6:67 https://doi.org/10.1186/s40425-018-0380-4

Journal for ImmunoTherapy of Cancer



# CrossMark A team effort: natural killer cells on the first leg of the tumor immunity relay race

Timothy B. Fessenden<sup>1</sup>, Ellen Duong<sup>2</sup> and Stefani Spranger<sup>1,2,3\*</sup>

# **Abstract**

Recent work by Böttcher and colleagues defines a new role for Natural Killer cells in the anti-tumor immune response, arriving early into the tumor microenvironment before passing the baton to DC1 dendritic cells. DC1 dendritic cells subsequently activate CD8+ T cells resulting in effective anti-tumor immunity. This work highlights the cooperative nature of anti-tumor immunity set in motion by Natural Killer cells, and immune evasion by tumors through their exclusion.

Sustained infiltration of CD8+ T cells into the tumor microenvironment has been shown to generate an immune suppressive microenvironment through the upregulation of immune inhibitory molecules, including PD-L1 (programmed death receptor ligand 1) on tumor cells or myeloid cells [\[1\]](#page-2-0). Accordingly, the majority of melanoma patients with a T-cell inflamed tumor microenvironment responds to checkpoint blockade therapy targeting immune inhibitory pathways such as PD-1:PD-L1 interactions, while non-T cell-inflamed tumors tend to be refractory to this therapy [\[2](#page-2-0)]. Unraveling the cellular and molecular determinants of T cell recruitment to and retention in solid tumors is therefore a crucial step toward improving existing immunotherapies.

Antigen-presenting cells, in particular dendritic cells (DC), are known to orchestrate initial activation of T cells in the tumor-draining lymph node [\[1\]](#page-2-0). In particular, cross-presenting CD103+ DC (also known as DC1 or  $Clec9a + DC$ ) appear to be critical for priming  $CD8+T$ cells [\[3](#page-2-0)]. Recent reports have defined a distinct role for CD103+ DC residing within the tumor microenvironment, where they cooperate with CD8+ cytotoxic T cells to recognize and clear tumor cells. Consequently, tumors able to exclude CD103+ DC can successfully evade T-cell mediated immune control [[4,](#page-2-0) [5](#page-2-0)]. However, our

Full list of author information is available at the end of the article



Böttcher et al. addressed this question using a melanoma tumor model previously reported to exclude T cells and CD103+ DC through the upregulation of cyclooxygenase enzymes COX-1 and COX-2 (encoded by ptgs1 and ptgs2) and their catalytic product, prostaglandin E2 (PGE2)  $[6]$  $[6]$ . In addition to the exclusion of CD103+ DC, they observed a stark reduction in the recruitment of Natural Killer (NK) cells into tumors [\[7](#page-2-0)]. Assessing the chemokine expression profile of tumor-residing immune cell subsets, the authors showed that XCL1 is produced exclusively by NK cells while CCL5 is secreted by both NK cells and CD8+ effector T cells. Both XCL1 and CCL5 as well as CCL4 have previously been reported to attract CD103+ DC to inflammatory sites through binding to XCR1/CCR5 chemokine receptors  $[4, 8]$  $[4, 8]$  $[4, 8]$  $[4, 8]$ , results that were confirmed in this study. In contrast to observations by Böttcher et al., however, previous studies found chemokine production originated from non-immune cells, suggesting that the source for chemokines might be highly context dependent.

Depletion of NK cells resulted in failed recruitment of CD103+ DC and immune evasion by tumors. In vitro analysis showed that tumor-derived PGE2 resulted in diminished secretion of CCL5 and XCL1 by NK cells and increased NK cell death [[7\]](#page-2-0). The observation of increased lymphocyte death in tumors with high levels of PGE2 agrees with previous reports. A study of ovarian cancer found that COX-2/PGE2 signaling caused increased expression of Fas-ligand on endothelial cells, which in turn increased apoptosis of infiltrating T cells and resulted



© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License [\(http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver [\(http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated.

<sup>\*</sup> Correspondence: [spranger@mit.edu](mailto:spranger@mit.edu) <sup>1</sup>

 $1$ Koch Institute for Integrative Cancer Research at MIT, 500 Main Street, Cambridge, MA 02139, USA

<sup>&</sup>lt;sup>2</sup>Massachusetts Institute of Technology, Department of Biology, Cambridge, USA

in a non-T cell-inflamed tumor microenvironment [[9](#page-2-0)]. Both studies show a cell death-related phenotype, however since NK cell death was observed ex vivo, the molecular mechanism appear to be distinct and should be fully elucidated.

The authors then validated their findings using patient samples and found that indeed NK cells are the dominant source of XCL1/2, while CD8+ effector T cells produce high levels of CCL5. Using human RNA transcript data, the authors provide further evidence supporting the concept that NK cells recruit CD103+ DC, which in turn are required for the recruitment of effector T cells. Previous work has shown that CD103+ DC are critical for the recruitment of effector T cells into the tumor microenvironment through the secretion of CXCL9 and CXCL10 [[5,](#page-2-0) [6\]](#page-2-0). Likewise, these studies provided evidence that restoration of CD103+ DC infiltration mediates regained responsiveness to immunotherapy.

Considering these observations in conjunction with those made by Böttcher and colleagues, it is plausible to suggest that anti-tumor immunity may operate as a relay race in which immune cells recruit each other to pass the tumor-reactive "baton" (See Fig. 1). Such cooperation ensures the sequential recruitment of NK cells, CD103+ DC, and most importantly CD8+ effector T cells into the tumor microenvironment. It is worth noting that, similar to effector T cells, NK cells can also be recruited by CXCL9 and CXCL10.

Meanwhile, CD8+ effector T cells are also a source of CCL4, CCL5 and XCL1. This redundancy in chemokine-mediated immune cell recruitment suggests a strong positive feedback loop, and highlights the importance of the recruitment and activation of early effector cells such as NK cells.

The canonical cytolytic role of NK cells can directly or indirectly contribute to tumor control.

However, Böttcher et al. make several intriguing observations regarding the role of NK cells during an anti-tumor immune response that go beyond their classically described function. The intriguing notion that innate lymphocytes can be recruited into the tumor at very early stages could explain the recruitment of CD103+ DC into tumors lacking chemokine production. In conjunction with the observation that PGE2 inhibits NK cell function, it could therefore be speculated that PGE2 mediates inhibition of anti-tumor immune responses at early stages of tumor development. Indeed, expression of cyclooxygenases and production of PGE2 has been linked to malignant transformation in multiple tissues and therefore is an early event in tumor development [\[10](#page-2-0)]. However, additional studies will be needed to elucidate how NK cells are activated and recruited into early tumor lesions. Similarly, whether NK cell activation is required in all cancer types to drive recruitment and retention of CD103+ DC and



CD8+ effector T cells merits further investigation. Determining the mechanism of NK cell recruitment could potentially lead to direct targeting of NK cell recruitment as a therapeutic target to start the tumor-immune "relay race." This therapeutic approach could convert immunotherapy-resistant, non-T cell-inflamed tumors into checkpoint blockade therapy-sensitive T cell-inflamed microenvironments, potentially independent of the tumor type and molecular mechanism for exclusion of CD103+ DC and CD8+ T cells.

### Funding

This work was funded by NCI R00CA204595 to SS.

### Authors' contributions

TF, ED, and SS wrote and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate Not Applicable

# Consent for publication

Not applicable

# <span id="page-2-0"></span>Competing interests

The authors declare that they have no competing interests.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**<br><sup>1</sup>Koch Institute for Integrative Cancer Research at MIT, 500 Main Street, Cambridge, MA 02139, USA. <sup>2</sup>Massachusetts Institute of Technology, Department of Biology, Cambridge, USA. <sup>3</sup>Howard S. and Linda B. Stern Career Development Professor, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.

## Received: 26 April 2018 Accepted: 20 June 2018 Published online: 09 July 2018

### References

- 1. Spranger S. Mechanisms of tumor escape in the context of the T-cellinflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol. 2016;28:383 –91.
- 2. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568 –71.
- 3. Engelhardt JJ, Boldajipour B, Beemiller P, Pandurangi P, Sorensen C, Werb Z, et al. Marginating dendritic cells of the tumor microenvironment crosspresent tumor antigens and stably engage tumor-specific T cells. Cancer Cell. 2012;21:402 –17.
- 4. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231 –5.
- 5. Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31:711 –723.e4.
- 6. Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162:1257 –70.
- 7. Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting Cancer immune control. Cell. 2018; 172:1022 –1037.e14.
- 8. Alexandre YO, Ghilas S, Sanchez C, Le Bon A, Crozat K, Dalod M. XCR1 dendritic cells promote memory CD8 T cell recall upon secondary infections with listeria monocytogenes or certain viruses. J Exp Med. 2016;213:75 –92.
- 9. Motz GT, Santoro SP, Wang L-P, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20:607 –15.
- 10. Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10: 181 –93.

#### Ready to submit your research? Choose BMC and benefit from:

- · fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- · maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

